Ranjna C. Dutta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ranjna C. Dutta has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Aroop K. Dutta
ExCel Matrix Biological Devices (P) Ltd, Hyderabad, India
3 shared publicationsA Puri
Division of Biochemistry, Central Drug Research Institute, Lucknow 226 001, India
1 shared publicationAroop K Dutta
1 shared publication- Bikramjit Basu
Laboratory for Biomaterials Science and Translational Research, Materials Research Centre, Indian Institute of Science, Bangalore 560012, India
1 shared publication Dinakar M. Salunke
1 shared publicationErwin Goldberg
Department of Biochemistry, Molecular Biology and Cell Biology Northwestern University, Evanston, IL, USA
1 shared publication
Latest Publications
- 1 March 2017
- Published by Elsevier in Biotechnology Advances
- Vol. 35 (2) , 240-250
Competent processing techniques for scaffolds in tissue engineering
- 1 March 2017
- Published by Elsevier in Biotechnology Advances
- Vol. 35 (2) , 240-250
Competent processing techniques for scaffolds in tissue engineering
- Open Access
- 12 February 2016
- Published by MedCrave Group Kft. in Journal of Analytical & Pharmaceutical Research
- Vol. 2 (2)
Targeting Efficiency of Immunliposome; Quantitative Assessment
- 12 February 2016
- Published by MedCrave Group Kft. in Journal of Analytical & Pharmaceutical Research
- Vol. 2 (2)
Open AccessTargeting Efficiency of Immunliposome; Quantitative Assessment
- 1 January 2012
- Vol. 4, 1043-8
ECM analog technology: a simple tool for exploring cell-ECM dynamics.
Cells in a functional tissue display a highly interactive relation with their neighboring cells and associated biochemical milieu. Serious disruption in the existing homeostatic balance in the extra-cellular matrix (ECM) may lead to abnormal response by the cells. With insufficient understanding of Cell-ECM interaction and in absence of simple tools for in vitro cell-culture in 3D, we still have to rely on the data generated by growing cells in 2D. In order to comprehend Cell-ECM dynamics it is important to recreate in vivo like microenvironment in 3D. Senescence and loss of function commonly observed in cells cultured in 2D are expected to be surmounted using such tools. Unlike prevailing belief that 3D culture is required only for tissue engineering (TE) and regenerative medicine, simple and easy to handle tools for ex vivo 3D culture may lead to greater impact. With the potential to improve our understanding about cellular behavior, both in normal and abnormal surroundings, they may eventually influence the diagnosis. Here we discuss some of the tools for cell culture in 3D, made available through novel cell-interactive ECM analog technology.
- 1 January 2012
- Vol. 4, 1043-8
ECM analog technology: a simple tool for exploring cell-ECM dynamics.
Cells in a functional tissue display a highly interactive relation with their neighboring cells and associated biochemical milieu. Serious disruption in the existing homeostatic balance in the extra-cellular matrix (ECM) may lead to abnormal response by the cells. With insufficient understanding of Cell-ECM interaction and in absence of simple tools for in vitro cell-culture in 3D, we still have to rely on the data generated by growing cells in 2D. In order to comprehend Cell-ECM dynamics it is important to recreate in vivo like microenvironment in 3D. Senescence and loss of function commonly observed in cells cultured in 2D are expected to be surmounted using such tools. Unlike prevailing belief that 3D culture is required only for tissue engineering (TE) and regenerative medicine, simple and easy to handle tools for ex vivo 3D culture may lead to greater impact. With the potential to improve our understanding about cellular behavior, both in normal and abnormal surroundings, they may eventually influence the diagnosis. Here we discuss some of the tools for cell culture in 3D, made available through novel cell-interactive ECM analog technology.
- 28 January 2011
- Published by Taylor & Francis in Therapeutic Delivery
- Vol. 2 (2) , 231-234
In Search of Optimal Scaffold for Regenerative Medicine and Therapeutic Delivery
Understanding extracellular matrix (ECM) biology is imperative for tissue engineering and regenerative medicine, which seeks functionally viable cells to be delivered at the site of injury in addition to restoring tissue/organ shape through artificial scaffolds. Cells cultured by conventional methods that allow only 2D growth are not the true representatives of functional cells existing in vivo. To expect an in vivo-like cellular response, it is mandatory to recreate an ECM-mimicking microenvironment, one of the fundamental needs of which is to allow cells to grow in a 3D scaffold. A convenient, user-friendly technology that can bridge the knowledge gaps and advance our comprehension of cell-cell and cell-ECM dynamics in a 3D environment is, therefore, the need of the hour. Such technologies can provide a novel tool for therapeutic delivery as well.
- 28 January 2011
- Published by Taylor & Francis in Therapeutic Delivery
- Vol. 2 (2) , 231-234
In Search of Optimal Scaffold for Regenerative Medicine and Therapeutic Delivery
Understanding extracellular matrix (ECM) biology is imperative for tissue engineering and regenerative medicine, which seeks functionally viable cells to be delivered at the site of injury in addition to restoring tissue/organ shape through artificial scaffolds. Cells cultured by conventional methods that allow only 2D growth are not the true representatives of functional cells existing in vivo. To expect an in vivo-like cellular response, it is mandatory to recreate an ECM-mimicking microenvironment, one of the fundamental needs of which is to allow cells to grow in a 3D scaffold. A convenient, user-friendly technology that can bridge the knowledge gaps and advance our comprehension of cell-cell and cell-ECM dynamics in a 3D environment is, therefore, the need of the hour. Such technologies can provide a novel tool for therapeutic delivery as well.
- 1 November 2010
- Published by Elsevier in Biotechnology Advances
- Vol. 28 (6) , 764-769
Comprehension of ECM-Cell dynamics: A prerequisite for tissue regeneration
- 1 November 2010
- Published by Elsevier in Biotechnology Advances
- Vol. 28 (6) , 764-769
Comprehension of ECM-Cell dynamics: A prerequisite for tissue regeneration
- 1 July 2009
- Published by Elsevier in Biotechnology Advances
- Vol. 27 (4) , 334-339
Cell-interactive 3D-scaffold; advances and applications
- 1 July 2009
- Published by Elsevier in Biotechnology Advances
- Vol. 27 (4) , 334-339
Cell-interactive 3D-scaffold; advances and applications
- 28 June 2008
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 60 (1) , 26-32
ORIGINAL ARTICLE: Testis Specific Lactate Dehydrogenase as Target for Immunoliposomes
Problem Is it possible to deliver therapeutic agents to testis through specific targeting?Method of study Immunoliposomes are designed by incorporating antibodies to lactate dehydrogenase‐C4 (LDH‐C4), which is the product of a testis specific gene. Their targeting and delivering ability is investigated in vitro and in vivo.Results It is observed that LDHC4‐immunoliposomes are able to discriminate and recognize antigens on spermatozoa and testes both in vitro and in vivo.Conclusion Specific targeting through LDH‐C4 appears to be a feasible strategy for delivering therapeutic as well as anti‐spermatogenic agents to testis.
- 28 June 2008
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 60 (1) , 26-32
ORIGINAL ARTICLE: Testis Specific Lactate Dehydrogenase as Target for Immunoliposomes
Problem Is it possible to deliver therapeutic agents to testis through specific targeting?Method of study Immunoliposomes are designed by incorporating antibodies to lactate dehydrogenase‐C4 (LDH‐C4), which is the product of a testis specific gene. Their targeting and delivering ability is investigated in vitro and in vivo.Results It is observed that LDHC4‐immunoliposomes are able to discriminate and recognize antigens on spermatozoa and testes both in vitro and in vivo.Conclusion Specific targeting through LDH‐C4 appears to be a feasible strategy for delivering therapeutic as well as anti‐spermatogenic agents to testis.
- 1 January 2008
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 40 (5) , 1005-1015
Functional mapping of apidaecin through secondary structure correlation
- 1 January 2008
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 40 (5) , 1005-1015
Functional mapping of apidaecin through secondary structure correlation
- 1 March 2007
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 13 (7) , 761-769
Drug Carriers in Pharmaceutical Design: Promises and Progress
Ever since pure molecular entities have been adapted as drug, varied manifestations other than elimination of infections are frequently been acknowledged as side effects. Contemporary drug research focuses on these issues besides developing new molecules for the restoration of unnatural functional deviations in various tissues and organs. The most promising advancement to achieve this concept of ideal drug is the encapsulation of drug in biocompatible nano or microspheres. Encapsulation can insulate the toxic drugs and lease a better half life to molecules undergoing spontaneous degradation under physiological conditions. It is also worthwhile to incorporate along some immunomodulators to strengthen and channelize the innate immune response of the host in right direction. This holistic approach would also prevent the physiological modulations dictated by invading pathogens, which paralyze the important functionaries of the host. Lipoproteins, lipid like molecules and probiotic non-colonizing bacterial membrane mimics might prove to be the best ingredients for encapsulation. Some synthetic non-immunogenic supra molecules like fullarenes and dendrimers also exhibit great potential for the development of new encapsulation technology. Here an attempt is made to review the progress in terms of aims and achievements in the area of drug carriers and encapsulation with its overall impact on therapeutic industry.
- 1 March 2007
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 13 (7) , 761-769
Drug Carriers in Pharmaceutical Design: Promises and Progress
Ever since pure molecular entities have been adapted as drug, varied manifestations other than elimination of infections are frequently been acknowledged as side effects. Contemporary drug research focuses on these issues besides developing new molecules for the restoration of unnatural functional deviations in various tissues and organs. The most promising advancement to achieve this concept of ideal drug is the encapsulation of drug in biocompatible nano or microspheres. Encapsulation can insulate the toxic drugs and lease a better half life to molecules undergoing spontaneous degradation under physiological conditions. It is also worthwhile to incorporate along some immunomodulators to strengthen and channelize the innate immune response of the host in right direction. This holistic approach would also prevent the physiological modulations dictated by invading pathogens, which paralyze the important functionaries of the host. Lipoproteins, lipid like molecules and probiotic non-colonizing bacterial membrane mimics might prove to be the best ingredients for encapsulation. Some synthetic non-immunogenic supra molecules like fullarenes and dendrimers also exhibit great potential for the development of new encapsulation technology. Here an attempt is made to review the progress in terms of aims and achievements in the area of drug carriers and encapsulation with its overall impact on therapeutic industry.
- 1 October 2002
- Published by Elsevier in Immunology Letters
- Vol. 83 (3) , 153-161
Peptide immunomodulators versus infection; an analysis
- 1 October 2002
- Published by Elsevier in Immunology Letters
- Vol. 83 (3) , 153-161
Peptide immunomodulators versus infection; an analysis